Carbon-Ion Radiotherapy Drives Ferroptosis and Immune Modulation in Gastric Cancer

Study Background and Research Question

Gastric cancer remains a leading cause of cancer-related mortality worldwide, with limited curative options for advanced-stage disease (paper). Radiotherapy is critical for patients with unresectable or metastatic tumors, but conventional photon-based modalities are often constrained by toxicity to surrounding tissues and tumor radioresistance—particularly in hypoxic microenvironments. Carbon-ion radiotherapy (CIRT), characterized by high linear energy transfer (LET) and a distinctive Bragg peak, offers enhanced dose precision and a higher relative biological effectiveness (RBE) compared to photons and protons (paper). Yet, the underlying mechanisms by which CIRT exerts anti-tumor effects in gastric cancer remain incompletely understood. A key focus of emerging research is ferroptosis, a regulated cell death pathway dependent on iron and lipid peroxidation, and its interplay with the tumor immune microenvironment. The enzyme dihydroorotate dehydrogenase (DHODH) is implicated in both cancer progression and radiosensitivity, but its role in mediating CIRT responses had not been established prior to this study.

Key Innovation from the Reference Study

Wang and Cai (2025) present a mechanistic advance by demonstrating that CIRT suppresses gastric cancer development through two convergent mechanisms: induction of ferroptosis and promotion of M1 macrophage polarization, both driven by DHODH downregulation (paper). By directly linking high-LET radiotherapy to immunogenic cell death and subsequent immune remodeling, the study identifies DHODH as a pivotal mediator and a potential therapeutic target to potentiate CIRT efficacy.

Methods and Experimental Design Insights

The authors employed a multi-level approach, integrating in vitro and in vivo models to dissect the molecular and cellular consequences of CIRT in gastric cancer:

• Cell Lines: Human gastric cancer cell lines HGC27 and AGS were exposed to CIRT doses (0, 2, and 4 Gy).
• Cellular Assays: Cell viability was measured using MTT assays; migration and invasion capacities were assessed with Transwell assays.
• Ferroptosis and Molecular Markers: Western blotting and quantitative RT-PCR were used to quantify DHODH, ferroptosis markers (e.g., ACSL4, GPX4), and to assess intracellular iron and reactive oxygen species (ROS) accumulation.
• Immune Analysis: Macrophage polarization was evaluated by flow cytometry following exposure to tumor-conditioned media from irradiated cells.
• Animal Models: BALB/c nude mice were implanted with AGS cells and randomized to control, CIRT, or DHODH-overexpressing + CIRT groups. Tumor growth and molecular endpoints were monitored.

This combination of molecular, cellular, and animal data provided a robust framework for mechanistic inference.

Protocol Parameters

• Western blot detection | Enhanced chemiluminescence (ECL) | Protein-level assessment of DHODH, ACSL4, GPX4 | Maximizes sensitivity for low-abundance markers post-CIRT | workflow_recommendation
• CIRT dose | 0, 2, 4 Gy | Dose-response evaluation of radiotherapy effects | Reflects clinically relevant irradiation exposures | paper
• Iron/ROS quantification | Colorimetric/fluorescent assay | Detects ferroptosis induction in treated cells | Validates oxidative stress as mechanistic link | paper
• Macrophage polarization | CD86+/CD206− flow cytometry | Distinguishes M1 vs. M2 phenotypes post-treatment | Directly assesses immune remodeling | paper
• Animal model | BALB/c nude mice, subcutaneous AGS xenografts | In vivo efficacy and biomarker validation | Models human gastric cancer progression | paper

Core Findings and Why They Matter

The study uncovers several interlinked outcomes that contribute to the anti-tumor efficacy of CIRT:

• DHODH Downregulation: CIRT significantly decreases DHODH expression in gastric cancer cells, correlating with reduced cell viability, migration, and invasion (paper).
• Ferroptosis Induction: Marked increases in intracellular iron and ROS, along with upregulation of ACSL4 and downregulation of GPX4, indicate robust ferroptotic cell death following CIRT exposure.
• Immune Modulation: Tumor-conditioned media from irradiated cells promote M1-like macrophage polarization (CD86+/CD206−), with increased expression of M1-associated cytokines. This suggests that CIRT not only triggers tumor cell death but also orchestrates a more pro-inflammatory tumor microenvironment.
• In Vivo Efficacy: CIRT substantially reduces tumor growth in xenograft models, and this effect is partially reversed by DHODH overexpression, confirming DHODH’s functional significance.

Collectively, these data position DHODH as a central node integrating metabolic, oxidative, and immune signals in response to high-LET radiotherapy.

Comparison with Existing Internal Articles

Internal resources such as "Carbon-Ion Radiotherapy Induces Ferroptosis in Gastric Cancer via DHODH Suppression" and "Carbon-Ion Radiotherapy Promotes Ferroptosis in Gastric Cancer" corroborate the central mechanistic role of DHODH downregulation and ferroptosis in CIRT-mediated tumor suppression. These articles emphasize translational perspectives but often focus on broader mechanistic pathways or therapeutic strategies. From a methodological standpoint, internal guides such as "ECL Chemiluminescent Substrate Detection Kit: Optimizing Sensitive Assays" and "ECL Chemiluminescent Kits: Accelerating Translational Oncology" detail how advanced chemiluminescent substrate kits empower sensitive detection of protein markers central to ferroptosis and immune modulation workflows. The present reference paper builds directly on these insights, illustrating how sensitive Western blot chemiluminescence detection is integral to robust mechanistic oncology studies.

Limitations and Transferability

While the study offers compelling evidence for DHODH as a mediator of CIRT efficacy in gastric cancer, several limitations merit consideration:

• Model Scope: The primary findings are limited to two human gastric cancer cell lines and mouse xenograft models. Heterogeneity in patient tumors and the clinical tumor microenvironment may modulate these responses (workflow_recommendation).
• Immune System Context: The use of immunodeficient mice constrains the ability to fully model adaptive immune responses to CIRT-induced ferroptosis (workflow_recommendation).
• DHODH Overexpression Rescue: While DHODH overexpression partially reversed CIRT efficacy, pharmacologic inhibition studies or genetic knockout models would further strengthen causal inference (workflow_recommendation).

Nevertheless, the mechanistic integration of ferroptosis and immune remodeling is likely relevant to other high-LET radiotherapies and may inform novel therapeutic combinations targeting redox metabolism and immunomodulation.

Research Support Resources

To recapitulate the sensitive protein detection workflows exemplified in this study—such as quantifying DHODH, ACSL4, and GPX4 in Western blot chemiluminescence detection or chemiluminescent immunoassay systems—researchers may utilize the ECL Chemiluminescent Substrate Detection Kit (SKU K1129). This chemiluminescent substrate kit is designed for robust and sensitive HRP-based detection of low-abundance proteins, supporting translational studies in oncology and cell death pathways (workflow_recommendation). For further methodological guidance, internal resources such as "ECL Chemiluminescent Substrate Detection Kit: Precision Western Blotting" (see internal guide) provide practical workflow enhancements and troubleshooting tips for assay optimization.